GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Inhalation Sciences Sweden AB (XSAT:ISAB) » Definitions » EBIT

Inhalation Sciences Sweden AB (XSAT:ISAB) EBIT : kr-5.07 Mil (TTM As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Inhalation Sciences Sweden AB EBIT?

Inhalation Sciences Sweden AB's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was kr-2.40 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was kr-5.07 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Inhalation Sciences Sweden AB's annualized ROC % for the quarter that ended in Dec. 2024 was -159.58%. Inhalation Sciences Sweden AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -351.01%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Inhalation Sciences Sweden AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -45.54%.


Inhalation Sciences Sweden AB EBIT Historical Data

The historical data trend for Inhalation Sciences Sweden AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhalation Sciences Sweden AB EBIT Chart

Inhalation Sciences Sweden AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.73 -16.57 -12.02 -3.75 -5.07

Inhalation Sciences Sweden AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.74 -0.78 -0.89 -1.00 -2.40

Competitive Comparison of Inhalation Sciences Sweden AB's EBIT

For the Medical Devices subindustry, Inhalation Sciences Sweden AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inhalation Sciences Sweden AB's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Inhalation Sciences Sweden AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Inhalation Sciences Sweden AB's EV-to-EBIT falls into.


;
;

Inhalation Sciences Sweden AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-5.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inhalation Sciences Sweden AB  (XSAT:ISAB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Inhalation Sciences Sweden AB's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=-9.624 * ( 1 - 0% )/( (6.898 + 5.164)/ 2 )
=-9.624/6.031
=-159.58 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Inhalation Sciences Sweden AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-9.6/( ( (0.542 + max(2.374, 0)) + (0.512 + max(2.042, 0)) )/ 2 )
=-9.6/( ( 2.916 + 2.554 )/ 2 )
=-9.6/2.735
=-351.01 %

where Working Capital is:

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.086 + 2.9 + 0) - (1.132 + 0 + 1.48)
=2.374

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.398 + 2.924 + 0) - (0.92 + 0 + 1.36)
=2.042

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Inhalation Sciences Sweden AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2024 )
=-5.07/11.134
=-45.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inhalation Sciences Sweden AB EBIT Related Terms

Thank you for viewing the detailed overview of Inhalation Sciences Sweden AB's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Inhalation Sciences Sweden AB Business Description

Traded in Other Exchanges
N/A
Address
Halsovagen 7, Huddinge, SWE, 141 57
Inhalation Sciences Sweden AB develops and commercializes patented lab instrument for inhalation research. Its products include PreciseInhale an advanced laboratory system used to measure inhaled particles and their effect on lungs, and LaminarPace tool for drying small amounts of the drug substance.

Inhalation Sciences Sweden AB Headlines

No Headlines